Compare TSSI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSSI | FHTX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.5M | 246.6M |
| IPO Year | N/A | 2020 |
| Metric | TSSI | FHTX |
|---|---|---|
| Price | $8.68 | $4.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.86 |
| AVG Volume (30 Days) | ★ 2.2M | 198.0K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.63 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $234,837,000.00 | $24,518,000.00 |
| Revenue This Year | N/A | $47.50 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $45.78 | ★ N/A |
| Revenue Growth | ★ 91.66 | N/A |
| 52 Week Low | $5.63 | $2.95 |
| 52 Week High | $31.94 | $7.42 |
| Indicator | TSSI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.57 | 47.16 |
| Support Level | $8.60 | $4.27 |
| Resistance Level | $9.48 | $4.87 |
| Average True Range (ATR) | 0.74 | 0.38 |
| MACD | 0.20 | -0.03 |
| Stochastic Oscillator | 53.05 | 7.77 |
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.